Drug Profile
RV 1729
Alternative Names: RV-1729Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator RespiVert
- Class Anti-inflammatories; Antiasthmatics; Bronchodilators; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in United Kingdom (Inhalation)
- 01 Jul 2015 RespiVert completes a phase I trial in Chronic obstructive pulmonary disease in United Kingdom (NCT02140346)